Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil ED90 for Respiratory Distress During Remimazolam Sedation
NCT06563063Completed
- Sponsor
- Yonsei University
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Open-label, single-arm trial of flumazenil in respiratory distress syndrome (RDS), sponsored by Yonsei University. Primary endpoint: Success or failure to improve respiratory distress. Started Aug 2023; status: completed.
02
Drugs
flumazenil
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT06563063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563063.